Literature DB >> 2954712

The effect of a novel taurine nitrosourea, 1-(2-chloroethyl)-3-[2-(dimethylaminosulfonyl)ethyl]-1-nitrosour ea (TCNU) on cytotoxicity, DNA crosslinking and glutathione reductase in lung carcinoma cell lines.

K D Tew, S W Dean, N W Gibson.   

Abstract

A novel nitrosourea, 1-(2-chloroethyl)-3-[2-(dimethylaminosulfonyl)ethyl]-1-nitrosourea (TCNU) has been investigated with respect to cytotoxic mechanisms in rat and human cell lines which either possess (Mer+) or lack (Mer-) 0(6)-alkylguanine transferase activity. TCNU produced significantly greater cytotoxicity in the Mer- cells (Walker 256 rat breast carcinoma resistant to nitrogen mustards; human lung carcinoma A427) than in the Mer+ cells (Walker 256 wild-type; human lung carcinoma A594). This correlated with results generated by alkaline elution studies which showed that TCNU caused DNA interstrand crosslinks in A427 but not in A549 cells. Inhibition of glutathione reductase activity by TCNU demonstrated that in carbamoylating activity the drug was intermediate between chlorozotocin and 1,(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in both A427 and A549 cells. These data suggest that the presence of taurine in the drug structure does little to alter the cytotoxicity or the alkylating or carbamoylating properties of TCNU, and that any clinical advantages with TCNU will be the consequence of other factors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2954712     DOI: 10.1007/bf00261475

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

1.  N-Bis (beta-chloroethyl) amino acids and related compounds as tumor-growth retarding agents.

Authors:  M ISHIDATE; Y SAKURAI; M IZUMI
Journal:  J Am Pharm Assoc Am Pharm Assoc       Date:  1955-03

2.  Concentration of taurine, beta-alanine, and triiodothyronine by ascites carcinoma cells.

Authors:  H N CHRISTENSEN; B HESS; T R RIGGS
Journal:  Cancer Res       Date:  1954-02       Impact factor: 12.701

3.  Hepatic glutathione reductase. I. Purification and general kinetic properties.

Authors:  C E MIZE; R G LANGDON
Journal:  J Biol Chem       Date:  1962-05       Impact factor: 5.157

4.  Selection of nitrogen mustard resistance in a rat tumor cell line results in loss of guanine-O6-alkyl transferase activity.

Authors:  S W Dean; N W Gibson; K D Tew
Journal:  Mol Pharmacol       Date:  1986-07       Impact factor: 4.436

5.  Carbamoylation of glutathione reductase and changes in cellular and chromosome morphology in a rat cell line resistant to nitrogen mustards but collaterally sensitive to nitrosoureas.

Authors:  K D Tew; G Kyle; A Johnson; A L Wang
Journal:  Cancer Res       Date:  1985-05       Impact factor: 12.701

6.  Changes in intracellular taurine content of human leukemic cells.

Authors:  K Wakayama; E C Besa; S I Baskin
Journal:  Nagoya J Med Sci       Date:  1983-06       Impact factor: 1.131

7.  DNA crosslinking and cytotoxicity in normal and transformed human cells treated with antitumor nitrosoureas.

Authors:  L C Erickson; M O Bradley; J M Ducore; R A Ewig; K W Kohn
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

8.  Inactivation of glutathione reductase by 2-chloroethyl nitrosourea-derived isocyanates.

Authors:  J R Babson; D J Reed
Journal:  Biochem Biophys Res Commun       Date:  1978-07-28       Impact factor: 3.575

9.  Taurine uptake by cultured human lymphoblastoid cells.

Authors:  H H Tallan; E Jacobson; C E Wright; K Schneidman; G E Gaull
Journal:  Life Sci       Date:  1983-11-07       Impact factor: 5.037

10.  Preferential effects of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) on pulmonary glutathione reductase and glutathione/glutathione disulfide ratios: possible implications for lung toxicity.

Authors:  A C Smith; M R Boyd
Journal:  J Pharmacol Exp Ther       Date:  1984-06       Impact factor: 4.030

View more
  1 in total

1.  Anti-tumour, toxicological and pharmacokinetic properties of a novel taurine-based nitrosourea (TCNU).

Authors:  B Hartley-Asp; P I Christensson; K Gunnarsson; P O Gunnarsson; G Jensen; J Polacek; A Stamvik
Journal:  Invest New Drugs       Date:  1988-04       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.